Carillon Tower Advisers’s BioTelemetry, Inc. BEAT Stock Holding History

Carillon Tower Advisers’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$7.04M	Sell	97,737 -4,700	-5%	-$246K	0.04%	366
2020 Q3	$4.67M	Sell	102,437 -3,352	-3%	-$140K	0.06%	341
2020 Q2	$4.78M	Sell	105,789 -359,318	-77%	-$16.1M	0.04%	374
2020 Q1	$16.7M	Sell	465,107 -11,300	-2%	-$520K	0.16%	196
2019 Q4	$22.1M	Sell	476,407 -4,200	-0.9%	-$182K	0.15%	241
2019 Q3	$19.6M	Sell	480,607 -600	-0.1%	-$25.9K	0.14%	251
2019 Q2	$23.2M	Buy	481,207 +2,575	+0.5%	+$135K	0.16%	230
2019 Q1	$30M	Buy	478,632 +354,043	+284%	+$24.3M	0.21%	176
2018 Q4	$7.44M	Sell	124,589 -14,000	-10%	-$841K	0.06%	329
2018 Q3	$8.93M	Sell	138,589 -11,015	-7%	-$615K	0.06%	349
2018 Q2	$6.73M	Sell	149,604 -2,496	-2%	-$99.5K	0.05%	360
2018 Q1	$4.72M	Buy	+152,100	New	+$5M	0.04%	371

Other funds holding BEAT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Governors Lane New York $1.2B AUM 26.21% 1-Year Est. Return

SGCM

Sand Grove Capital Management London, United Kingdom $383M AUM 123.08% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return

Carillon Tower Advisers's BEAT Position: Q4 2020 in Review

Carillon Tower Advisers reduced its BioTelemetry, Inc. (BEAT) stake by 4.6% in Q4 2020, selling an estimated $246K and leaving 97,737 shares worth $7.04M. The position accounts for 0.04% of the portfolio, ranked #366.

Carillon Tower Advisers first reported a position in BEAT in Q1 2018 and has held it in 12 quarters since. The position peaked at $30M in Q1 2019. 238 funds tracked by Wall St. Rank hold BEAT as of Q4 2020.

Carillon Tower Advisers held 97,737 shares of BioTelemetry, Inc. worth $7.04M as of Q4 2020.
Carillon Tower Advisers sold 4,700 BioTelemetry, Inc. shares in Q4 2020, an estimated $246K.
BioTelemetry, Inc. made up 0.04% of Carillon Tower Advisers's portfolio in Q4 2020, its #366 holding.
Carillon Tower Advisers first reported a position in BioTelemetry, Inc. in Q1 2018 and has held it in 12 quarters since.
Carillon Tower Advisers's BioTelemetry, Inc. position peaked at $30M in Q1 2019.
238 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.